Tissue Glucocorticoid Metabolism in Adrenal Insufficiency: A Prospective Study of Dual-release Hydrocortisone Therapy
The Journal of Clinical Endocrinology & Metabolism · 2023
DOI: 10.1210/clinem/dgad370 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Rosemary A Dineen und 28 weiteren Autor:innen. Beteiligte Einrichtung: Academic Department of Endocrinology, Beaumont Hospital/Royal College of Surgeons in Ireland, Dublin, D09 YD60, Ireland. Hauptthemen laut MEDLINE: Glucocorticoids, Adrenal Insufficiency. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Irish Research Council, The Meath Foundation, Irish Endocrine Society.
Abstract (Originalsprache)
Background
Patients with adrenal insufficiency (AI) require life-long glucocorticoid (GC) replacement therapy. Within tissues, cortisol (F) availability is under the control of the isozymes of 11β-hydroxysteroid dehydrogenase (11β-HSD). We hypothesize that corticosteroid metabolism is altered in patients with AI because of the nonphysiological pattern of current immediate release hydrocortisone (IR-HC) replacement therapy. The use of a once-daily dual-release hydrocortisone (DR-HC) preparation, (Plenadren®), offers a more physiological cortisol profile and may alter corticosteroid metabolism in vivo. Study Design and Methods Prospective crossover study assessing the impact of 12 weeks of DR-HC on systemic GC metabolism (urinary steroid metabolome profiling), cortisol activation in the liver (cortisone acetate challenge test), and subcutaneous adipose tissue (microdialysis, biopsy for gene expression analysis) in 51 patients with AI (primary and secondary) in comparison to IR-HC treatment and age- and BMI-matched controls.
Results
Patients with AI receiving IR-HC had a higher median 24-hour urinary excretion of cortisol compared with healthy controls (72.1 µg/24 hours [IQR 43.6-124.2] vs 51.9 µg/24 hours [35.5-72.3], P = .02), with lower global activity of 11β-HSD2 and higher 5-alpha reductase activity. Following the switch from IR-HC to DR-HC therapy, there was a significant reduction in urinary cortisol and total GC metabolite excretion, which was most significant in the evening. There was an increase in 11β-HSD2 activity. Hepatic 11β-HSD1 activity was not significantly altered after switching to DR-HC, but there was a significant reduction in the expression and activity of 11β-HSD1 in subcutaneous adipose tissue.
Conclusion
Using comprehensive in vivo techniques, we have demonstrated abnormalities in corticosteroid metabolism in patients with primary and secondary AI receiving IR-HC. This dysregulation of pre-receptor glucocorticoid metabolism results in enhanced glucocorticoid activation in adipose tissue, which was ameliorated by treatment with DR-HC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Academic Department of Endocrinology, Beaumont Hospital/Royal College of Surgeons in Ireland, Dublin, D09 YD60, Ireland.
- Robert Graves Institute of Endocrinology, Tallaght University Hospital, Dublin, D24 TP66, Ireland.
- Institute of Metabolism and Systems Research, University of Birmingham, Birmingham B15 2TT, UK.
- Department of Clinical Science, University of Bergen, 5021 Bergen, Norway.
- Faculty of Medicine and Health, University of Leeds, Leeds LS2 9JT, UK.
- Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, Churchill Hospital, University of Oxford, Oxford OX3 7LE, UK.
ORCID-Profile: Rosemary A Dineen, Julie Martin-Grace, Angela E Taylor, Lina Schiffer, Gareth G Lavery, Anjuli Gunness, Aoife Garrahy, Anne Marie Hannon, Paal Methlie, Paul M Stewart, Jeremy W Tomlinson, Brian G Keevil, Lucy-Ann Behan, Wiebke Arlt, Mark Sherlock
Förderung
- The Irish Research Council
- The Meath Foundation
- Irish Endocrine Society
- Shire Ltd
Zitieren
APA
Dineen, R. A., Martin-Grace, J., Ahmed, K. M. S., Taylor, A. E., Shaheen, F., Schiffer, L., Gilligan, L. C., Lavery, G. G., Frizelle, I., Gunness, A., Garrahy, A., Hannon, A. M., Methlie, P., Eystein, S. H., Stewart, P. M., Tomlinson, J. W., Hawley, J. M., Keevil, B. G., O'Reilly, M. W., …, & Sherlock, M. (2023). Tissue Glucocorticoid Metabolism in Adrenal Insufficiency: A Prospective Study of Dual-release Hydrocortisone Therapy. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad370
Vancouver
Dineen RA, Martin-Grace J, Ahmed KMS, Taylor AE, Shaheen F, Schiffer L, et al. Tissue Glucocorticoid Metabolism in Adrenal Insufficiency: A Prospective Study of Dual-release Hydrocortisone Therapy. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad370
BibTeX
@article{Dineen2023,
author = {Dineen, Rosemary A and Martin-Grace, Julie and Ahmed, Khalid Mohamed Saeed and Taylor, Angela E and Shaheen, Fozia and Schiffer, Lina and Gilligan, Lorna C and Lavery, Gareth G and Frizelle, Isolda and Gunness, Anjuli and Garrahy, Aoife and Hannon, Anne Marie and Methlie, Paal and Eystein, Sverre Husebye and Stewart, Paul M and Tomlinson, Jeremy W and Hawley, James M and Keevil, Brian G and O'Reilly, Michael W and Smith, Diarmuid and McDermott, John and Healy, Marie-Louise and Agha, Amar and Pazderska, Agnieszka and Gibney, James and Behan, Lucy-Ann and Thompson, Chris J and Arlt, Wiebke and Sherlock, Mark},
title = {Tissue Glucocorticoid Metabolism in Adrenal Insufficiency: A Prospective Study of Dual-release Hydrocortisone Therapy},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
doi = {10.1210/clinem/dgad370}
}
EUVIMED